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for analyses. Median age at transplant was 29 (range, 0-76).
58% received stem cells from related donors. 78% received
bone marrow, 14% received peripheral blood stem cell, and
8% received cord blood. 77% received myeloablative condi-
tioning. Median follow-up for survivors was 7 years (range, 2
to 28). A total of 57,766 person-years were observed. 6,884
recipients were followed for more than 5 years (32,438
person years for observation period of 5 years or longer).
Standarized mortality ratio (observed / expected ratio) was
calculated for comparison with general population in Japan
for speciﬁc causes of death.
Results: Among relapse-free survivors at 2 years, overall
survival at 10 years, 15years were 86%, and 82%. Probabilities
were 95% and 91% when subjects were limited to relapse-
free survivors at 5 years. When compared to general pop-
ulation in Japan, risk of overall mortality was signiﬁcantly
higher (observed / expected ratio [O/E] ¼ 15.1, 95%CI, 14.3-
16.0). The risk of mortality was signiﬁcantly higher with
infection (O/E¼89.8, 95%CI, 77.4-100.7), new malignancy (O/
E¼3.2, 95%CI, 2.6-4.0), cardiovascular (O/E¼2.3, 95%CI, 1.5-
3.5), respiratory (O/E¼150.9, 95%CI, 131.1-172.5) including
chronic obstructive lung disease (O/E¼182.2, 95%CI, 101.2-
214.1), digestive (O/E¼4.2, 95%CI, 1.4-9.7), liver (O/E¼10.5,
95%CI, 7.4-14.8), kidney-genitourinary (O/E¼23.6, 95%CI,
13.1-37.1), and external cause (O/E¼2.5, 95%CI, 1.5-3.8)
compared to general population. The risk of death from any
cause was approximately twenty times higher from 2 to 4
years after transplant for relapse-free survivors at 2 years (O/
E¼21.1, 95%CI, 19.6-22.6) compared to general population.
The risk was still ten times higher with statistical signiﬁcance
for the subjects after 5 years post transplant (O/E¼10.0, 95%
CI, 9.1-11.0).
Conclusions: Long-term survivors after allogeneic HCTare at
higher risk of mortality due to various causes other than
underlying diseases. Screening and preventive practices are
important for long-term follow up of HCT recipients.75
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Late onset non-infectious pulmonary injury complicates
>10% of allogeneic stem cell transplants (SCT), particularly in
subjects conditioned with high dose Total Body Irradiation
(TBI), and contributes to transplant related mortality. To
characterize the kinetics of recovery from pulmonary injury
in long term survivors we collected data on 138 (78 male, 60
female) subjects surviving>5 years after SCT from their HLA-
matched siblings. The median age at transplant was 36 years.
Transplant indications were CML (63), AML (31), MDS (19),
ALL (12) and others (14). 126 subjects received 1200 cGy
TBI-based conditioning with or without lung shielding, 3
received 400 cGy TBI-based conditioning and 9 patients
received no irradiation. Ex vivo T cell depleted grafts were
given to 131 recipients, except for six who received a non-
myeloablative SCT. Of the 138 long term survivors, 26 had no
cGvHD, 70 had cGvHD lasting less than 3 years; and 42 had
prolonged cGvHD requiring systemic immunosuppression
for> 3 years. Among the 17 patients who died after 5 years, 4died of pulmonary causes, including two with lung cancer.
Pre-transplant abnormalities (< 80% predicted) in PFTs were
found in 15.9% of subjects in the following declining
frequency: FVC%, VC, TLC, FEV1, DLCO_Adj (adjusted for
hemoglobin and alveolar ventilation) Hb/VA and FEV1/FVC.
Baseline (BL) PFTs served as the reference for all subsequent
measurements at 3, 5, 10 and 15 years for each survivor. The
only parameter showing a clinically signiﬁcant decline post
transplant was DLCO_Adj which reached a nadir at 5 years,
with subsequent normalization at the 10 yearmark [paired t-
test]. An abnormal (<80% of baseline) DLCOAdj was found in
19.6, 21.0, 0.7 and 0% of survivors at 3, 5, 10 and 15 years. The
mean DLCO_Adj at 3, 5, 10 and 15 years were 91% (P ¼ .003),
88% (P < .001), 98% (p¼NS) and 100% (p¼NS) of BL, respec-
tively. Multivariable modeling (forward-stepwise multiple
regression) identiﬁed the presence of chronic GVHD
(P ¼ .017) and abnormal Baseline DLCO_Adj (P ¼ .023) as the
only signiﬁcant factors associated with the decline in
DLCO_Adj at 5 years but excluded smoking, conditioning
intensity, baseline C-reactive protein level, TBI dose to the
lungs and demographic variables. In conclusion, DLCO_Adj is
the only PFT marker associated with pulmonary injury in our
TBI-conditioned transplant population. DLCO_Adj nadirs at 5
years post-SCT, and normalizes by 10 years. Chronic GVHD
and pre-transplant DLCO_Adj are important contributory
factors to the decline in DLCO_Adj.76
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Background: Several recent studies have examined the use
of sirolimus (SIR) and tacrolimus (TAC) for prevention of
graft-versus-host disease (GVHD). Data are sparse, however,
regarding patient-reported quality of life (QOL) associated
with this regimen. We report an analysis of QOL outcomes in
the ﬁrst year post-transplant from a randomized controlled
trial of (SIR/TAC) compared to methotrexate (MTX)/TAC.
